---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039902"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:30:13.397107+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma reports Q3 net loss $6.1M; FDA supports MAT2203 Phase 3 with LPAD pathway

## Summary
- Net loss of $6.1M ($0.03 per share) in Q3 2023 vs $5.5M in Q3 2022; no revenue vs $1.1M from BioNTech in prior year.
- Cash $18.2M at Sep 30, 2023; runway into Q3 2024; seeking non-dilutive BARDA funding.
- FDA agreed MAT2203 Phase 3 design for invasive aspergillosis with limited treatment options; acknowledged LPAD registration pathway.
- FDA open to superiority composite endpoint to strengthen commercial positioning without increasing study size (<200 patients).
- Patient with Candida krusei achieved complete clinical resolution after 2 weeks on MAT2203; new fusarium patient enrolled at Vanderbilt.

## SEC filing metadata
- accession: 0001493152-23-039902
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039902/0001493152-23-039902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315223039902/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039902
- JSON: https://secwatch.observer/filing/0001493152-23-039902.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.